U.S. markets open in 2 hours 41 minutes

Abiomed, Inc. (ABMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
256.66+2.10 (+0.82%)
At close: 04:00PM EDT
256.67 +0.01 (+0.00%)
After hours: 04:10PM EDT

Abiomed, Inc.

22 Cherry Hill Drive
Danvers, MA 01923
United States
978 646 1400

IndustryMedical Devices
Full Time Employees2,003

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael R. MinogueChairman, CEO & Pres3.04M26.95M1967
Mr. Todd A. TrappExec. VP & CFO914.93kN/A1971
Mr. Marc A. BeganExec. VP, Gen. Counsel & Sec.818.64kN/A1967
Mr. Andrew J. GreenfieldExec. VP & Chief Commercial Officer804.95kN/A1973
Dr. David M. Weber Ph.D.Scientific & Technology Advisor1.02M6.79M1961
Mr. Matthew T. PlanoExec. VP of Global Operations & IntegrationN/AN/A1965
Dr. Thorsten Siess Ph.D.VP & CTON/AN/AN/A
Ms. Ingrid Goldberg WardDirector of Investor RelationsN/AN/AN/A
Sarah KarrCommunications Mang.N/AN/AN/A
Mr. Michael G. HowleyVP & GM of Global SalesN/AN/A1964
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Corporate Governance

Abiomed, Inc.’s ISS Governance QualityScore as of July 1, 2022 is 10. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.